Evidence map›Paper›PMID 33767426›Full record

ArticleNature immunology2021

The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-β pathway.

Mariko Takahashi, Chan-Wang J Lio, Anaamika Campeau, Martin Steger, Ferhat Ay, Matthias Mann, David J Gonzalez, Mohit Jain, Sonia Sharma

Open access · greenAbstract read
In one paragraph

Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 106 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mariko Takahashi *La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-2465-7907
Chan-Wang J Lio *La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3876-6741
Anaamika CampeauDepartment of Pharmacology, University of California, San Diego, San Diego, CA, USA.
Martin StegerMax Planck Institute of Biochemistry, Martinsried, Germany.
Ferhat AyLa Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0708-6914
Matthias MannMax Planck Institute of Biochemistry, Martinsried, Germany.ORCID http://orcid.org/0000-0003-1292-4799
David J GonzalezDepartment of Pharmacology, University of California, San Diego, San Diego, CA, USA.
Mohit JainDepartment of Pharmacology, University of California, San Diego, San Diego, CA, USA.
Sonia SharmaLa Jolla Institute for Immunology, La Jolla, CA, USA. soniasharma@lji.org.ORCID http://orcid.org/0000-0002-6556-1963
La Jolla Institute for Immunology · USUniversity of California San Diego · USEvotec (Germany) · DEMax Planck Institute of Biochemistry · DE

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2U54CA260591 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., KARIN, MICHAEL · 2020 to 2024
$9.1M
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
Rheumatic Diseases Research Training GrantT32AR064194 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARY S FIRESTEIN, Monica Guma · 2013 to 2026
$3.8M
Mapping the Plasma Exposome and its Association with Human Cardiovascular DiseaseR01ES027595 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAIN, MOHIT · 2017 to 2021
$3.3M
Targeting tumor endothelium for cancer surveillance and immunotherapyR01CA199376 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SHARMA, SONIA · 2015 to 2019
$2.0M
RapidFire mass spectrometry systemS10OD020025 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAIN, MOHIT · 2015 to 2015
$600k
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514k
NCI NIH HHS R01 CA199376NCI NIH HHS U54 CA260591NCRR NIH HHS S10 RR027366NIAMS NIH HHS T32 AR064194NIDCR NIH HHS U01 DE028227NIEHS NIH HHS R01 ES027595NIGMS NIH HHS T32 GM007752NIH HHS S10 OD020025
6 · The paper itself

Abstract

Evasion of host immunity is a hallmark of cancer; however, mechanisms linking oncogenic mutations and immune escape are incompletely understood. Through loss-of-function screening of 1,001 tumor suppressor genes, we identified death-associated protein kinase 3 (DAPK3) as a previously unrecognized driver of anti-tumor immunity through the stimulator of interferon genes (STING) pathway of cytosolic DNA sensing. Loss of DAPK3 expression or kinase activity impaired STING activation and interferon (IFN)-β-stimulated gene induction. DAPK3 deficiency in IFN-β-producing tumors drove rapid growth and reduced infiltration of CD103

Indexed as

Immunity, InnateTumor EscapeAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDeath-Associated Protein KinasesFemaleGene Expression Regulation, NeoplasticHumansHuman Umbilical Vein Endothelial CellsImmune Checkpoint InhibitorsInterferon-betaLIM Domain ProteinsMembrane ProteinsMiceMice, Inbred C57BLDAPK3 protein, humanDapk3 protein, mouseDeath-Associated Protein KinasesImmune Checkpoint InhibitorsInterferon-betaLIM Domain ProteinsLMO7 protein, humanLmo7 protein, mouseMembrane ProteinsSTING1 protein, humanSting1 protein, mouseSTING ProteinTranscription Factors

Identifiers

PMID33767426
PMCPMC8300883
OpenAlexW3137439833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.